Increasing our understanding of the cellular mechanisms responsible for laterality defects using zebrafish model is critical for the development of therapeutic approaches and devising early intervention strategies in humans during development.
Key areas of discussion include:
Manush Mohammed, Research Instructor, Developmental Biology , University of Pittsburgh Medical School
Jeffrey Essner, Associate Professor, Department of Genetics, Development & Cell Biology, Iowa State University
Dr. Essner received his Ph.D. from the University of Minnesota with Dr. Perry Hackett, where he began using the zebrafish model system to understand the cellular roles of proto-oncogenes. Prior to joining the faculty of the Genetics, Development and Cell Biology Department at Iowa State University in 2005, Dr. Essner was the Scientific Director at Discovery Genomics, Inc., a biotech company that uses zebrafish for high-throughput analysis of gene function. At Iowa State University, Dr. Essner has developed methods for targeted mutagenesis using TALENs and CRISPR/Cas9 for modeling human disease in zebrafish with a focus on angiogenesis and cancer progression.
Given the enormous impact CRISPR gene editing is set to have in developing gene therapies, the industry are advancing and adapting the technology to get it ready for clinical use.
Questions that will be addressed include:
Christian Mueller, Associate Professor, Pediatrics & Gene Therapy Center , University of Massachusetts Medical School